自體幹細胞/非幹細胞治療市場報告：2030 年趨勢、預測與競爭分析

自體幹細胞/非幹細胞治療的趨勢和預測

至2030年，全球自體幹細胞和非幹細胞治療市場預計將達到130億美元，2024年至2030年的複合年成長率為10.2%。該市場的主要驅動力是對微創治療的需求不斷成長、幹細胞和非幹細胞治療方法的快速技術進步以及政府對促進再生醫學應用的支持不斷增加。全球自體幹細胞和非幹細胞治療市場的未來前景看好，醫院和門診手術中心市場充滿機會。

• Lucintel 預測，由於癌症盛行率和治療方法的擴大，以及自體幹細胞治療的使用不斷增加，癌症和腫瘤學預計將在預測期內實現最高成長。
• 由於該地區慢性病患病率高、對微創手術的強勁需求以及有利的政府報銷政策，預計北美地區在預測期內將出現最高的成長。

自體幹細胞/非幹細胞治療市場新趨勢

自體幹細胞/非幹細胞治療市場的新興趨勢包括技術進步、監管變化和臨床應用的變化。這些趨勢將重塑再生醫學的未來並確保市場成長。

• 強調個人化醫療：藥物日益個人化是自體幹細胞治療市場日益強調個人化的一部分。透過患者的特定基因圖譜實現的高度個人化在提高效率和減少副作用方面取得了重大成功。因此，這一趨勢推動了更客製化的治療，以改善患者的預後。
• 細胞處理技術的進步：新的細胞處理技術正在提高幹細胞治療的有效性。其技術力包括自動化細胞處理技術和細胞擴增方法，以獲得更高品質和更多數量的治療細胞。這無疑將進一步增加自體幹細胞治療的可行性和擴充性。
• 擴大臨床應用：幹細胞和非幹細胞治療方法的臨床應用即將經歷爆炸性成長。目前正在研究針對影響心血管系統、神經系統和整形外科疾病的疾病和損傷的新治療方法。這加強了再生醫學發展的基礎，並繼續為市場成長提供機會。
• 非幹細胞療法的開發：在開發不使用純幹細胞的治療方法正在取得進展，例如組織工程和基因編輯。這些是再生醫學的新方法，補充了使用幹細胞的傳統治療方法。此類發明增加了治療選擇並推動市場成長。
• 監管發展和核准：由於監管機構的持續努力，該領域的進一步發展將繼續推動新治療方法的核准和商業化。簡化監管流程以及增加對創新治療方法的支持，將鼓勵自體和非幹細胞治療方法的進一步開發和適應，實現更好的市場准入，並加快創新步伐。

新興國家的這些趨勢正在透過個人化醫療的進步、細胞處理技術的改進、臨床應用的擴展、其他替代療法的開發以及順利的監管核准來推動自體幹細胞和非幹細胞治療市場的發展。這促進了創新並持續提高再生醫學的有效性。

自體幹細胞/非幹細胞治療市場的最新趨勢

自體和非幹細胞治療的關鍵發展代表了技術和臨床的變化。這表明該研究領域是充滿活力的，並且對健康的影響越來越大。

• 新治療方法的核准FDA 等多個機構核准新的自體幹細胞療法，擴大了治療範圍，並為患有慢性疾病或損傷的患者提供了更多的治療選擇。其他活動包括心血管和自體免疫疾病的先進治療，這是反映該領域進展的活躍領域。
• 細胞處理的創新：細胞處理的新技術包括自動化系統和擴增方法的改進，使幹細胞治療更加有效和強大。這些技術進步將促進高品質治療細胞的產生並改善治療的可及性。
• 非幹細胞治療方法的成長：預計組織工程和基因療法等非幹細胞療法的市場也將顯著成長。這些領域的新前沿正在開發各種再生醫學方法，並補充基於幹細胞應用的傳統方法。
• 擴大研究和臨床試驗：增加自體和非幹細胞療法的研究和臨床試驗，開發新治療方法，研究新應用，加深我們對治療功效和安全性的理解也在取得進展。
• 個人化治療的進步：該市場的主要趨勢之一是根據患者情況創建個人化治療。基於基因型和臨床資訊的客製自訂治療正在透過走向個人化醫療來改善治療結果並減少不利事件。

這些新增內容正在透過新的治療方法、細胞處理技術、擴大的研究、臨床試驗和個人化治療方法影響自體幹細胞和非幹細胞治療市場。這是成長背後的驅動力，將再生醫學推向更有效的水平。

自體幹細胞/非幹細胞治療市場的策略性成長機會

隨著技術的進步和應用的擴大，自體幹細胞和非幹細胞治療市場的成長機會不斷出現，塑造再生醫學領域的未來並進一步擴大市場。

• 腫瘤治療：此外，正在研究幹細胞療法用於癌症治療和康復的腫瘤學領域代表著一個重大的成長機會。先進的細胞療法和組織工程技術正在為各種癌症類型的管理和治療提供新的治療方法並不斷增加市場潛力。
• 心血管應用：隨著用於心臟修復和再生的幹細胞療法的發展，心血管應用仍然是主要成長領域之一。心血管疾病的細胞療法透過滿足未滿足的需求並產生擴大治療選擇的創新來推動市場成長。
• 神經系統疾病：神經系統疾病的治療被認為是一個新的成長機會。帕金森氏症和脊髓損傷是正在研究使用或不使用幹細胞治療的疾病的例子。這開闢了有效治療的新途徑，並擴大了市場應用的可能性。
• 整形外科創傷：另一個不斷成長的領域是整形外科創傷和病症，其中幹細胞療法被考慮用於軟骨修復和骨再生。再生醫學的最新進展已開始為肌肉骨骼損傷提供新的解決方案，改善復健並促進市場成長。
• 糖尿病監測：即透過幹細胞療法管理糖尿病，包括胰島素生成細胞的再生。使用糖尿病細胞的治療創新正在開啟糖尿病管理和改善患者治療結果的新領域。

自體幹細胞和非幹細胞療法的策略性成長機會是由腫瘤學、心血管應用、神經系統疾病、整形外科損傷和糖尿病管理相關的進步所推動的。這將擴大再生醫學的範圍並推動廣泛治療領域的創新。

自體幹細胞/非幹細胞治療市場的促進因素與挑戰

主要的市場促進因素和挑戰正在塑造自體幹細胞和非幹細胞治療市場的成長方向和趨勢。在流動和成長要素中，技術進步、經濟因素和監管考量對市場的塑造起著重要作用。

推動自體幹細胞和非幹細胞治療市場的因素包括：

1.技術進步：影像處理、細胞處理和治療技術的技術進步是促進市場成長的因素之一。自動化細胞處理和先進的基因編輯是最近的創新概念之一，它們提高了幹細胞和非幹細胞療法的功效和效率，擴大了臨床應用範圍。

2.再生醫學需求上升：再生醫學需求上升是推動市場的主要因素之一。因此，患者和醫療保健提供者越來越需要慢性和退化性疾病的先進治療方法，幹細胞和非幹細胞治療正在被廣泛採用。這將促進進一步的市場成長和創新。

3.臨床應用的擴展：幹細胞和非幹細胞療法臨床應用的擴展正在推動這個市場。此外，針對癌症、心血管疾病和神經系統疾病等多種疾病的新治療方法正在擴大再生醫學的範圍並增加市場機會。

4. 增加研發投資：增加研發投資將促進自體和非幹細胞治療市場的創新。這些資金來自公共和私營部門，支持創造和開發新的治療方法和技術，以改善市場和增加競爭。

5. 監管支持和核准：新治療方法的核准和商業化的明確監管途徑、改善市場進入以及更快地推出新治療方法。

自體幹細胞/非幹細胞治療市場的挑戰包括：

1. 監管障礙：克服複雜的監管要求並提供新的治療方法以獲得核准是很複雜的。此外，關於引入和採用幹細胞和非幹細胞新治療方法的法規的地區差異極為嚴格。

2.開發成本高：高成本是先進治療方法開發和製造過程中的主要挑戰之一。這是由於與研究、開發和製造相關的成本，這可能會限制可用性和承受能力，特別是對於價格敏感的市場。為了廣泛滲透市場，成本控制是絕對必要的。

3.倫理和安全問題：與使用幹細胞的研究和治療方法相關的倫理和安全問題被認為是最重要的問題之一。必須深入討論知情同意、潛在風險和長期治療結果等問題，以獲得公眾信任並獲得監管部門的核准。

自體幹細胞和非幹細胞治療市場的成長促進因素是技術進步、再生醫學需求的增加、臨床應用的擴大、研發投資的增加和監管支持。主要瓶頸包括監管障礙、高昂的開發成本和道德問題。透過加強應對這些市場促進因素和挑戰，將實現更好的市場成長和創新。

自體幹細胞/非幹細胞分段治療方法

本研究按產品類型、類型、應用、最終用途和地區對全球自體幹細胞和非幹細胞療法進行了預測。

自體幹細胞/非幹細胞治療市場的國家前景

近年來，由於技術創新和臨床應用的推廣，自體幹細胞/非幹細胞治療市場得到了顯著的發展。這些發生在美國、中國、德國、印度和日本，反映了再生醫學的全球發展及其融入主流醫療系統。

• 美國：在美國，自體幹細胞療法已作為一種新治療方法獲得FDA批准並開始臨床試驗。該市場日益受到心血管和自體免疫疾病等多種適應症的個人化治療的推動。細胞處理和保存技術的改進正在提高這些治療方法的有效性和可及性。
• 中國：因此，中國在幹細胞和非幹細胞療法方面都取得了進展，並且在臨床研究和商業化方面正在經歷快速成長。最近的趨勢包括擴大幹細胞銀行服務以及增加再生醫學相關研究的資金。中國研究機構正在利用先進的幹細胞技術探索癌症和神經系統疾病的新治療方法。
• 德國：然而，在將自體幹細胞治療納入常規臨床管理方面，德國是領先國家。最近的趨勢包括針對整形外科和皮膚科疾病引入新的幹細胞療法。德國在實施治療時非常重視品管和病人安全。
• 印度：由於醫療保健投資增加以及患者對更好醫療服務的需求，印度市場是幹細胞和非幹細胞治療的新興市場。最近，印度開發了利用幹細胞治療慢性疾病的先進療法，並建立了專門從事再生醫學的新研究設施。由於治療費用負擔較低，獲得先進醫療保健的機會也在改善。
• 日本：日本在自體細胞和非幹細胞治療方面取得了可比較的進展。日本正在尋找新的應用，包括治療與老齡化相關的退化性疾病。最近的發展包括用於治療神經退化性疾病的細胞療法的成功以及高效細胞收集和處理新技術的引入。

常問問題

Q.1 自體幹細胞/非幹細胞治療的市場規模有多大？

A1. 到 2030 年，全球自體幹細胞和非幹細胞治療市場預計將達到 130 億美元。

Q.2 自體幹細胞/非幹細胞治療市場的成長預測如何？

A2. 預計2024年至2030年全球自體幹細胞/非幹細胞治療市場將以10.2%的複合年成長率成長。

Q.3 影響自體幹細胞/非幹細胞治療市場成長的關鍵促進因素有哪些？

A3. 該市場的主要驅動力是對微創治療的需求不斷成長、幹細胞和非幹細胞治療方法的快速技術進步以及政府為促進再生醫學的使用而採取的支持措施不斷增加。

Q4.市場的主要細分市場是：

A4. 自體幹細胞和非幹細胞治療市場前景廣闊，醫院市場和門診手術中心市場充滿機會。

Q5.市場的主要企業是：

A5. 自體幹細胞/非幹細胞治療的主要企業如下：

• BrainStorm Cell
• Cytori Therapeutics
• Dendreon Pharmaceuticals
• Novartis
• US Stem Cell

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預測，由於癌症盛行率和治療方法的擴大，以及自體幹細胞治療的使用不斷增加，癌症和腫瘤學將在預測期內呈現最高成長。

Q7. 未來五年預計哪些地區的市場成長最大？

A7. 由於慢性病的高盛行率、對微創手術的強勁需求以及該地區政府將提供有利的報銷政策，預計北美地區將在預測期內出現最高的成長。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球自體幹細胞/非幹細胞治療市場：市場動態

• 簡介、背景、分類
• 供應鏈
• 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

• 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
• 全球自體幹細胞/非幹細胞治療市場趨勢（2018-2023）與預測（2024-2030）
• 按產品類型分類的自體幹細胞和非幹細胞治療的全球市場
  • 血壓監測裝置
  • 肺壓監測裝置
  • 顱內壓監測裝置
• 自體幹細胞/非幹細胞治療市場（按類型）
  • 自體幹細胞
  • 自體非幹細胞
• 按應用分類的自體幹細胞/非幹細胞治療的全球市場
  • 神經退化性疾病
  • 自體免疫疾病
  • 癌症/腫瘤
  • 心血管疾病
• 按最終用途分類的全球自體幹細胞和非幹細胞治療市場
  • 醫院
  • 門診手術中心
  • 其他

第4章 2018-2030年區域市場趨勢及預測分析

• 按地區分類的全球自體幹細胞/非幹細胞治療市場
• 北美自體幹細胞/非幹細胞治療市場
• 歐洲自體幹細胞/非幹細胞治療市場
• 亞太地區自體幹細胞/非幹細胞治療市場
• 其他地區自體幹細胞/非幹細胞治療市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 按產品類型分類的全球自體幹細胞和非幹細胞治療市場成長機會
  • 全球自體幹細胞/非幹細胞治療市場的成長機會（按類型）
  • 全球自體幹細胞/非幹細胞治療市場的成長機會（按應用）
  • 按最終用途分類的全球自體幹細胞和非幹細胞治療市場的成長機會
  • 按地區分類的全球自體幹細胞和非幹細胞治療市場成長機會
• 全球自體幹細胞/非幹細胞治療市場新趨勢
• 戰略分析
  • 新產品開發
  • 擴大全球自體幹細胞/非幹細胞治療市場的產能
  • 全球自體幹細胞和非幹細胞治療市場的合併、收購和合資企業
  • 認證和許可

第7章主要企業概況

• BrainStorm Cell
• Cytori Therapeutics
• Dendreon Pharmaceuticals
• Novartis
• US Stem Cell

Autologous Stem Cell and Non-Stem Cell Based Therapy Trends and Forecast

The future of the global autologous stem cell and non-stem cell based therapy market looks promising with opportunities in the hospital and ambulatory surgical center markets. The global autologous stem cell and non-stem cell based therapy market is expected to reach an estimated $13.0 billion by 2030 with a CAGR of 10.2% from 2024 to 2030. The major drivers for this market are growing demand for minimally invasive procedures, rapid technological advancements in stem cell and non-stem cell-based therapies, and rising supportive government initiatives to promote the use of regenerative medicine.

• Lucintel forecasts that cancer & tumor is expected to witness highest growth over the forecast period due to the rising use of autologous therapy along with the expanding incidence of cancer cases and treatments.
• North America is expected to witness highest growth over the forecast period due to the high prevalence of chronic diseases, existence of significant demand for minimally invasive procedures, and availability of favorable government reimbursement policies in the region.

Emerging Trends in the Autologous Stem Cell and Non-Stem Cell Based Therapy Market

Emerging trends in autologous stem cell- and non-stem cell-based therapy markets reveal evolving technology, changes in regulation, and changing clinical application. These are the trends that will reshape the future of regenerative medicine and ensure market growth.

• Greater Emphasis on Personalized Medicine: This increasing personalization of medicines is part of the growing emphasis in the autologous stem cell therapy market. The high level of personalization that has come through the particular genetic profile of the patient has gone a long way in providing increased efficiency with lesser side effects. This trend is, therefore, a push toward more customized therapies for better patient outcomes.
• Cell Processing Technology Advancement: Newer cell-processing technologies are increasing the effectiveness of stem cell treatments. The technological capabilities include automated cell processing and cell expansion methods that yield higher-quality and more numerous therapeutic cells. This will no doubt further enhance the feasibility and scalability of autologous stem cell treatments.
• Clinical Applications Expansion: Clinical applications for both stem cell and non-stem cell-based therapies are set for explosive growth. New treatments are being researched for diseases and injuries affecting the cardiovascular system, the nervous system, and orthopedic ailments. This continues to enhance the platform in which regenerative medicine is being developed while continuing to create more opportunities for market growth.
• Development of Non-Stem Cell Therapies: There has been progress in developing non-pure stem cell-based therapies, such as tissue engineering and gene editing. These represent other modes of regenerative medicine and supplementation of more traditional approaches to treatment that involve the use of stem cells. Such inventions improve the therapeutic options and drive market growth.
• Regulatory Advances and Approvals: Further development of the field through ongoing regulatory efforts will continue to facilitate approval and commercialization for new therapies. Streamlining regulatory processes, along with increased support for innovative treatments, will help further develop and adapt autologous stem cell and non-stem cell-based therapies, allowing better market access and forcing the pace of innovation.

These emerging trends are revolutionizing the autologous stem cell and non-stem cell-based therapy market by advancements in personalized medicine, improved cell processing technologies, expanded clinical uses, development of other alternatives, and smooth regulatory approvals. This, when put together, drives innovation and enhances the effectiveness of regenerative medicine continuously.

Recent Developments in the Autologous Stem Cell and Non-Stem Cell Based Therapy Market

Some of the key developments in autologous stem cell and non-stem cell-based therapies mark the change in technology and clinical practice. This thus denotes that the area of study is dynamic, with an increased impact on health.

• Approval of New Therapies: Adding new autologous stem cell therapies passed by the different bodies like the FDA has increased the scope of therapy and opened up treatment options for patients ailing from chronic diseases and injuries. Other areas include advanced treatments for cardiovascular conditions and autoimmune disorders, active areas reflecting ongoing progress in the field.
• Innovation in Cell Processing: New technologies for cell processing involve automated systems and improved expansion methodologies that make stem cell therapies more effective and powerful. Thus, these advances in the technology are promoting the generation of high-quality therapeutic cells and better access to treatments.
• Growth in Non-Stem Cell-Based Therapies: It is also estimated that the market is significantly growing in the non-stem cell based therapies such as tissue engineering and gene therapy. New frontiers in these fields have now opened up different approaches towards regenerative medicine and supplement traditional approaches based upon the application of stem cells.
• Expansion of Research and Clinical Trials: While research and clinical trials in both autologous stem cell and non-stem cell-based therapies have increased, the same growth brings about new therapies, investigates new applications, and refines the understanding of therapeutic efficacy and safety.
• Advancements in Personalized Treatment: One of the major developments in this market is the creation of treatments personalized to the patient profile. Custom therapies based on genotype and clinical information are improving treatment outcomes and reducing adverse events by moving toward individualized medicine.

These additions are affecting the autologous stem cell and non-stem cell-based therapy market in new therapies, technology of cell processing, expanded research, clinical trials, and personalized treatment approaches. This drives growth that is going to push regenerative medicine to another level of effectiveness.

Strategic Growth Opportunities for Autologous Stem Cell and Non-Stem Cell Based Therapy Market

Growth opportunities in autologous stem cell and non-stem cell-based therapy markets continue to emerge with technological advancement and increasing applications, thus shaping the future in the area of regenerative medicine and further expanding markets.

• Oncology Treatments: Further, oncology represents a huge growth opportunity wherein the use of stem cell therapies is being explored for the treatment and recuperation of cancer. Newer treatment modalities are being offered by advanced cell therapy and tissue engineering techniques for the management and treatment of different types of cancer, along with increasing market potential.
• Cardiovascular Applications: Cardiovascular applications continue to be one of the major growth areas, and the development of stem cell therapies for repair and regeneration of the heart will also occur. Cell-based treatments for cardiovascular disease are producing innovations that are meeting unmet needs and extending treatment options, driving the market growth.
• Neurological Disorders: Treatment of neurological disorders may be considered an emerging growth opportunity. Parkinson's disease and spinal cord injuries are but two examples of medical conditions that are being studied with treatments both involving and not involving the use of stem cells. New avenues for effective treatments thus become available while the circles of market application are expanded.
• Orthopedic Traumas: Other growth areas include orthopaedic injuries and conditions, in which stem cell therapies are considered for the repair of cartilage and regeneration of bone. With recent advances made within regenerative medicine, new solutions have started to be provided to musculoskeletal injuries, improving recovery and contributing to the market growth.
• Monitoring of Diabetes: This, therefore, presents a very important growth opportunity: the management of diabetes with the use of stem cell therapies, including insulin-producing cell regeneration. Diabetes cell-based treatment innovations are opening new frontiers for the management of the disease and improvement of patients' outcomes.

The strategic growth opportunities in autologous stem cell and non-stem cell-based therapy markets are driven by advancements related to oncology, cardiovascular applications, neurological disorders, orthopaedic injuries, and diabetes management. This is a broadening the scope for regenerative medicine and driving innovation across wide therapeutic areas.

Autologous Stem Cell and Non-Stem Cell Based Therapy Market Driver and Challenges

Major drivers and challenges shape the direction of growth and development of the autologous stem cell and non-stem cell-based therapy market. In terms of flux or growth, technological advancement, economic factors, and regulatory considerations have played an influential role in shaping the market.

The factors responsible for driving the autologous stem cell and non-stem cell based therapy market include:

1. Technological Advances: Technological advancements in imaging, cell processing, and therapy techniques are amongst the factors contributing to the growth of the market. Automation of cell processing and advanced genetic editing are amongst the recent innovative concepts improving efficacy and efficiency in both stem cell and non-stem cell-based therapies, hence widening their clinical application scope.

2. Increasing Demand for Regenerative Medicine: The increasing demand for regenerative medicine is one of the major driving factors for the market. Therefore, patients and healthcare providers increasingly need therapies with advanced treatments for chronic and degenerative conditions, thereby fueling the wider adoption of both stem cell and non-stem cell-based therapies. This fosters further market growth and innovation.

3. Clinical Applications Expansion: But this is being driven by the expansion of clinical applications for both stem cell and non-stem cell-based therapies. Further, newer treatments for a range of disease conditions including cancer, cardiovascular diseases, and neurological disorders are expanding the scope of regenerative medicine and increasing market opportunities.

4. Growing Investment in Research and Development: Increased investment in research and development propels innovation into the autologous stem cell-and non-stem cell-based therapy market. This funding emanates from both the public and private sectors and supports the creation and development of new therapies and technologies that drive improvement and competitiveness in the market.

5. Regulatory Support and Approvals: These include support at the regulatory level by way of smooth approval processes: clearer pathways from regulatory bodies for the approval and commercialization of new therapies, better market access, and quickened introduction of new treatments.

Challenges in the autologous stem cell and non-stem cell based therapy market are:

1. Regulatory Hurdles: It is complicated to overcome complex regulatory requirements and make approvals possible by offering new kinds of therapies. The regional variations in regulations would also be very tough when it comes to high-stringency approval processes for the introduction and adoption of new stem cell and non-stem cell-based therapies.

2. High Development Costs: High cost is one of the major challenges in the development or manufacturing process of any advanced therapy. This may be due to costs related to research, development, and production, which could limit accessibility and affordability, especially for more price-sensitive markets. For wider access to the market, cost management becomes an absolute necessity for broader market penetration.

3. Ethical and Safety Issues: Ethical and safety issues with regards to research and therapies involving stem cells are considered some of the most major challenges. Issues of informed consent, risk potential, and long-term results have to be discussed in depth for winning public trust and gaining regulatory approval.

The growth drivers for the autologous stem cell and non-stem cell-based therapy market are technological advancements, increasing demand for regenerative medicine, increasing clinical applications, rising investment in R&D, and regulatory support. Major bottlenecks include regulatory hurdles, high development costs, and ethical issues. With more and more effort being put into addressing these drivers and challenges, better growth and innovation will be achieved in the market.

List of Autologous Stem Cell and Non-Stem Cell Based Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies autologous stem cell and non-stem cell based therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the autologous stem cell and non-stem cell based therapy companies profiled in this report include-

• BrainStorm Cell
• Cytori Therapeutics
• Dendreon Pharmaceuticals
• Novartis
• U.S. Stem Cell

Autologous Stem Cell and Non-Stem Cell Based Therapy by Segment

The study includes a forecast for the global autologous stem cell and non-stem cell based therapy by product type, type, application, end use, and region.

Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Product Type [Analysis by Value from 2018 to 2030]:

• Blood Pressure Monitoring Devices
• Pulmonary Pressure Monitoring Devices
• Intracranial Pressure Monitoring Devices

Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Type [Analysis by Value from 2018 to 2030]:

• Autologous Stem Cells
• Autologous Non-Stem Cells

Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application [Analysis by Value from 2018 to 2030]:

• Neurodegenerative Disorders
• Autoimmune Diseases
• Cancer & Tumors
• Cardiovascular Diseases

Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospitals
• Ambulatory Surgical Centers
• Others

Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Autologous Stem Cell and Non-Stem Cell Based Therapy Market

The autologous stem cell and non-stem cell-based therapy market has developed a lot in recent times owing to technological innovations and wider clinical applications. These are taking place in the United States, China, Germany, India, and Japan and reflect global developments in regenerative medicine and its incorporation into the mainstream health care system.

• United States: Within the United States, autologous stem cell therapy has seen new therapies currently approved by the FDA, while clinical trials have also been initiated to explore its other uses. The market is observing an upswing in personalized treatments for various indications, including cardiovascular diseases and autoimmune disorders. Improving technologies for cell processing and storage are serving to amplify the efficacy and access associated with these therapies.
• China: Thus, China has advanced in both the stem cell and non-stem cell-based therapies, putting much effort into rapid growth in both clinical research and commercialization. Development in recent times has been, among other things, the development of expanded services for stem cell banking and increased funding in research that relates to regenerative medicine. Chinese institutions explore new treatments for cancer and neurological disorders using advanced stem cell techniques.
• Germany: Nevertheless, Germany is the leader in terms of the integration of autologous stem cell therapies into everyday clinical management, with serious attention to regulatory compliance and, at the same time, effectively providing clinical efficacy. Recent developments in this country include the adoption of new stem cell-based treatments for orthopedic and dermatological conditions. Quality control and patient safety have been emphasized to a very high standard regarding the implementation of therapy in Germany.
• India: The Indian market is a developing market for both stem cell-based therapies and non-stem cell-based therapies, owing to increased investment in the health care and growing demand of patients for better health services. Recently, this country has developed advanced treatments using stem cells for chronic diseases and the establishment of new research facilities with special focus on regenerative medicine. Cost-friendly options for therapies increase access to advanced treatments.
• Japan: Japan has recorded equal progress in both autologous stem cell therapies and non-stem cell-based treatments. The country is looking toward new applications involving the treatment of age-related and degenerative diseases. Recent developments include success with cell therapy used for treating neurodegenerative disorders and new technologies introduced for efficient harvesting and processing of the cells.

Features of the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market

Market Size Estimates: Autologous stem cell and non-stem cell based therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Autologous stem cell and non-stem cell based therapy market size by various segments, such as by product type, type, application, end use, and region in terms of value ($B).

Regional Analysis: Autologous stem cell and non-stem cell based therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, types, applications, end uses, and regions for the autologous stem cell and non-stem cell based therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the autologous stem cell and non-stem cell based therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the autologous stem cell and non-stem cell based therapy market size?

Answer: The global autologous stem cell and non-stem cell based therapy market is expected to reach an estimated $13.0 billion by 2030.

Q.2 What is the growth forecast for autologous stem cell and non-stem cell based therapy market?

Answer: The global autologous stem cell and non-stem cell based therapy market is expected to grow with a CAGR of 10.2% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the autologous stem cell and non-stem cell based therapy market?

Answer: The major drivers for this market are growing demand for minimally invasive procedures, rapid technological advancements in stem cell and non-stem cell-based therapies, and rising supportive government initiatives to promote the use of regenerative medicine.

Q4. What are the major segments for autologous stem cell and non-stem cell based therapy market?

Answer: The future of the autologous stem cell and non-stem cell based therapy market looks promising with opportunities in the hospital and ambulatory surgical center markets.

Q5. Who are the key autologous stem cell and non-stem cell based therapy market companies?

Answer: Some of the key autologous stem cell and non-stem cell based therapy companies are as follows:

• BrainStorm Cell
• Cytori Therapeutics
• Dendreon Pharmaceuticals
• Novartis
• U.S. Stem Cell

Q6. Which autologous stem cell and non-stem cell based therapy market segment will be the largest in future?

Answer: Lucintel forecasts that cancer & tumor is expected to witness highest growth over the forecast period due to the rising use of autologous therapy along with the expanding incidence of cancer cases and treatments.

Q7. In autologous stem cell and non-stem cell based therapy market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to the high prevalence of chronic diseases, existence of significant demand for minimally invasive procedures, and availability of favorable government reimbursement policies in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the autologous stem cell and non-stem cell based therapy market by product type (blood pressure monitoring devices, pulmonary pressure monitoring devices, and intracranial pressure monitoring devices), type (autologous stem cells and autologous non-stem cells), application (neurodegenerative disorders, autoimmune diseases, cancer & tumors, and cardiovascular diseases), end use (hospitals, ambulatory surgical centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Product Type
  • 3.3.1: Blood Pressure Monitoring Devices
  • 3.3.2: Pulmonary Pressure Monitoring Devices
  • 3.3.3: Intracranial Pressure Monitoring Devices
• 3.4: Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Type
  • 3.4.1: Autologous Stem Cells
  • 3.4.2: Autologous Non-Stem Cells
• 3.5: Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application
  • 3.5.1: Neurodegenerative Disorders
  • 3.5.2: Autoimmune Diseases
  • 3.5.3: Cancer & Tumors
  • 3.5.4: Cardiovascular Diseases
• 3.6: Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use
  • 3.6.1: Hospitals
  • 3.6.2: Ambulatory Surgical Centers
  • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Region
• 4.2: North American Autologous Stem Cell and Non-Stem Cell Based Therapy Market
  • 4.2.1: North American Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application: Neurodegenerative Disorders, Autoimmune Diseases, Cancer & Tumors, and Cardiovascular Diseases
  • 4.2.2: North American Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use: Hospitals, Ambulatory Surgical Centers, and Others
• 4.3: European Autologous Stem Cell and Non-Stem Cell Based Therapy Market
  • 4.3.1: European Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application: Neurodegenerative Disorders, Autoimmune Diseases, Cancer & Tumors, and Cardiovascular Diseases
  • 4.3.2: European Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use: Hospitals, Ambulatory Surgical Centers, and Others
• 4.4: APAC Autologous Stem Cell and Non-Stem Cell Based Therapy Market
  • 4.4.1: APAC Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application: Neurodegenerative Disorders, Autoimmune Diseases, Cancer & Tumors, and Cardiovascular Diseases
  • 4.4.2: APAC Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use: Hospitals, Ambulatory Surgical Centers, and Others
• 4.5: ROW Autologous Stem Cell and Non-Stem Cell Based Therapy Market
  • 4.5.1: ROW Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application: Neurodegenerative Disorders, Autoimmune Diseases, Cancer & Tumors, and Cardiovascular Diseases
  • 4.5.2: ROW Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use: Hospitals, Ambulatory Surgical Centers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Product Type
  • 6.1.2: Growth Opportunities for the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Type
  • 6.1.3: Growth Opportunities for the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Application
  • 6.1.4: Growth Opportunities for the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by End Use
  • 6.1.5: Growth Opportunities for the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market by Region
• 6.2: Emerging Trends in the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: BrainStorm Cell
• 7.2: Cytori Therapeutics
• 7.3: Dendreon Pharmaceuticals
• 7.4: Novartis
• 7.5: U.S. Stem Cell